<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHOSLOÂ - calcium acetateÂ capsuleÂ </strong><br>Fresenius Medical Care North America<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">PhosLo <br>
(calcium acetate)<br>These highlights do not include all the information needed to use PhosLo safely and effectively. see full prescribing information for PhosLo.<br><br>PhosLo (Calcium Acetate) CAPSULE for ORAL use.<br>Initial U.S. Approval: 1990</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul><li> PhosLoÂ® is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. (<a href="#s010">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Starting dose is 2 gelcaps with each meal. (<a href="#s020">2</a>)</li>
<li> Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached.Â  Most patients require 3-4 gelcaps with each meal. (<a href="#s020">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li> Capsule:Â  667 mg calcium acetate gelcap. (<a href="#s030">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li> <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>. (<a href="#s040">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Treat mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by reducing or interrupting PhosLoÂ® and Vitamin D.Â  Severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may require hemodialysis and discontinuation of PhosLoÂ®. (<a href="#becd383a-2004-4d55-a001-e0353789c6d3">5.1</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may aggravate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. (<a href="#s052">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul>
<li> The most common (&gt;10%) adverse reactions are <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#b7f1b1ed-bb8e-4b72-af5f-8f3c5555ac23">6.1</a>).</li>
<li> In clinical studies, patients have occasionally experienced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> during calcium acetate therapy. (<a href="#s060">6</a>).<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or <span class="Bold Italics">www.fda.gov/medwatch.</span></span>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> PhosLoÂ® may decrease the bioavailability of tetracyclines or fluoroquinolones. (<a href="#s070">7</a>)</li>
<li> When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after PhosLoÂ®, or consider monitoring blood levels of the drug. (<a href="#s070">7</a>)</li>
</ul></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION
</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4Â  CONTRAINDICATIONS
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5Â  WARNINGS AND PRECAUTIONS
</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold Italics">5.1 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>
</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold Italics">5.2 Concomitant Use with Medications
</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6Â  ADVERSE REACTIONS
</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold Italics">6.1 Clinical Trials Experience
</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold Italics">6.2 Postmarketing Experience
</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7Â  DRUG INTERACTIONS
</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold Italics">7.1 Ciprofloxacin
</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS
</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold Italics">8.1 PREGNANCY
</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold Italics">8.2Â  LABOR &amp; DELIVERY
</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold Italics">8.3Â  NURSING MOTHERS
</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold Italics">8.4Â  PEDIATRIC USE
</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold Italics">8.5Â  GERIATRIC USE
</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10Â  OVERDOSAGE
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11Â  DESCRIPTION
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12Â  CLINICAL PHARMACOLOGY
</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold Italics">12.1Â  MECHANISM OF ACTION
</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold Italics">12.2Â  PHARMACODYNAMICS
</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13Â  NONCLINICAL TOXICOLOGY
</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold Italics">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY
</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14Â  CLINICAL STUDIES
</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING
</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s010"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1Â  INDICATIONS &amp; USAGE
</span></h1>
<p class="First">PhosLoÂ® is a phosphate binder indicated to reduce serum phosphorus in patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s020"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2Â  DOSAGE &amp; ADMINISTRATION
</span></h1>
<p class="First">The recommended initial dose of PhosLoÂ® for the adult dialysis patient is 2 gelcaps with each meal.Â  Increase the dose gradually to lower serum phosphorus levels to the target range, as long as <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> does not develop.Â  Most patients require 3-4 gelcaps with each meal.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s030"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3Â  DOSAGE FORMS &amp; STRENGTHS
</span></h1>
<p class="First">Capsule:Â  667 mg calcium acetate per gelcap.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s040"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4Â  CONTRAINDICATIONS
</span></h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5Â  WARNINGS AND PRECAUTIONS
</span></h1>
<div class="Section">
<a name="becd383a-2004-4d55-a001-e0353789c6d3"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold Italics">5.1 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>
</span></h2>
<p class="First">Patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> may develop <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> when treated with calcium, including calcium acetate (PhosLoÂ®).Â  Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with PhosLoÂ®.</p>
<p>An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of PhosLo may lead to progressive <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, which may require emergency measures.Â  Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly.Â  Should <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> develop, reduce the PhosLoÂ® dosage or discontinue the treatment, depending on the severity of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<p>More severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (Ca&gt;12 mg/dL) is associated with <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.Â  Severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> can be treated by acute hemodialysis and discontinuing PhosLoÂ® therapy.</p>
<p>Mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.Â  Mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> is usually controlled by reducing the PhosLoÂ® dose or temporarily discontinuing therapy.Â  Decreasing or discontinuing Vitamin D therapy is recommended as well.</p>
<p>Chronic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may lead to <span class="product-label-link" type="condition" conceptid="4030365" conceptname="Vascular calcification">vascular calcification</span> and other soft-tissue calcification.Â  Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification.Â  The long term effect of PhosLoÂ® on the progression of vascular or soft tissue calcification has not been determined.</p>
<p><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> (&gt;11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.</p>
<p>Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg<span class="Sup">2</span>/dL<span class="Sup">2</span>.</p>
</div>
<div class="Section">
<a name="s052"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold Italics">5.2 Concomitant Use with Medications
</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may aggravate <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s060"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6Â  ADVERSE REACTIONS
</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> is discussed elsewhere <a href="#becd383a-2004-4d55-a001-e0353789c6d3">[see Warnings and Precautions (5.1)]</a>.</p>
<div class="Section">
<a name="b7f1b1ed-bb8e-4b72-af5f-8f3c5555ac23"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold Italics">6.1 Clinical Trials Experience
</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In clinical studies, calcium acetate has been generally well tolerated.</p>
<p>PhosLoÂ® was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients.Â  Adverse reactions (&gt;2% on treatment) from these trials are presented in Table 1.</p>
<table frame="void" width="607">
<caption><span> Table 1: Adverse Reactions in Patients with End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> Undergoing Hemodialysis</span></caption>
<thead>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" rowspan="2" valign="top"><span class="Bold">Preferred Term</span></td>
<td class="BotruleLruleRruleToprule" align="center" rowspan="2" valign="middle">
<span class="Bold"> Total adverse reactions reported for calcium acetate</span><span class="Bold"><br></span><span class="Bold">n = 167</span><span class="Bold"><br></span>n (%)</td>
<td class="BotruleLruleRruleToprule" align="center" rowspan="2" valign="middle">
<span class="Bold"> 3-mo, open-label study of calcium acetate </span><span class="Bold"><br></span><span class="Bold">n = 98 </span><br>n (%)</td>
<td class="BotruleLruleRruleToprule" align="center" colspan="2" valign="middle">
<span class="Bold"> Double-blind, placebo-controlled, cross-over study of calcium acetate </span><span class="Bold"><br></span><span class="Bold">n = 69</span>
</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">
<span class="Bold">Calcium acetate</span><br>n (%)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">
<span class="Bold">Placebo</span><br>n (%)</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">6 (3.6)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">6 (6.1)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0 (0.0)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0 (0.0)</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">4 (2.4)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">4 (4.1)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0 (0.0)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0 (0.0)</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">21 (12.6)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">16 (16.3)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">5 (7.2)</td>
<td class="BotruleLruleRruleToprule" align="center" valign="top">0 (0.0)</td>
</tr>
</tbody>
</table>
<p>Mild <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be asymptomatic or manifest itself as <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, neusea, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.Â  More severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> is associated with <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.Â  Decreasing dialysate calcium concentration could reduce the incidence and severity of PhosLoÂ®-induced <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.Â  Isolated cases of <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> have been reported, which may represent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
<div class="Section">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold Italics">6.2 Postmarketing Experience
</span></h2>
<p class="First">Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.</p>
<p>The following additional adverse reactions have been identified during post-approval of calcium acetate:Â  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s070"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7Â  DRUG INTERACTIONS
</span></h1>
<p class="First">The drug interaction of PhosLoÂ® is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl and hydroxyl groups).Â  PhosLoÂ® may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.</p>
<p>There are no empirical data on avoiding drug interactions between calcium acetate or PhosLoÂ® and most concomitant drugs.Â  When administering an oral medication with PhosLoÂ® where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after PhosLoÂ® or calcium acetate.Â  Monitor blood levels of the concomitant drugs that have a narrow therapeutic range.Â  Patients taking anti-arrhythmic medications for the control of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medications for the control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders were excluded from the clinical trials with all forms of calcium acetate.</p>
<div class="Section">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold Italics">7.1 Ciprofloxacin
</span></h2>
<p class="First">In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets approximately 2.7 g, decreased the bioavailability of ciprofloxacin by approximately 50%.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8Â  USE IN SPECIFIC POPULATIONS
</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">8.1 PREGNANCY
</span></h2>
<p class="First">Pregnancy Category C</p>
<p>PhosLoÂ® contains calcium acetate.Â  Animal reproduction studies have not been conducted with PhosLoÂ®, and there are no adequate and well controlled studies of PhosloÂ® use in pregnant women.Â  Patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> may develop <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> with calcium acetate treatment <span class="Italics"><a href="#becd383a-2004-4d55-a001-e0353789c6d3">[see Warnings and Precautions (5.1)]</a></span>.Â  Maintenance of normal serum calcium levels is important for maternal and fetal well being.Â  <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> during pregnancy may increase the risk for maternal and neonatal complications such as <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span>, preterm delivery, and neonatal <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span>.Â  PhosLoÂ® treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics">8.2Â  LABOR &amp; DELIVERY
</span></h2>
<p class="First">The effects of PhosLoÂ® on labor and delivery are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics">8.3Â  NURSING MOTHERS
</span></h2>
<p class="First">PhosLoÂ® contains calcium acetate and is excreted in human milk.Â  Human milk feeding by a mother receiving PhosLoÂ® is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">8.4Â  PEDIATRIC USE
</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold Italics">8.5Â  GERIATRIC USE
</span></h2>
<p class="First">Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.Â  Other clinical experience has not identified differences in responses between the elderly and younger patients.Â  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10Â  OVERDOSAGE
</span></h1>
<p class="First">Administration of PhosLoÂ® in excess of the appropriate daily dosage may result in <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> <span class="Italics"><a href="#becd383a-2004-4d55-a001-e0353789c6d3">[see Warnings and Precautions (5.1)]</a></span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11Â  DESCRIPTION
</span></h1>
<p class="First">PhosLoÂ® acts as a phosphate binder.Â  Its chemical name is calcium acetate.Â  Its molecular formula is C<span class="Sub">4</span>H<span class="Sub">6</span>CaO<span class="Sub">4</span>, and its molecular weight is 158.17.Â  Its structural formula is:</p>
<dl>
<dt></dt>
<dd><p class="First"><img alt="99a9c435-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=34a29fae-b549-41ed-bd7d-e98fe2110bef&amp;name=99a9c435-figure-01.jpg"></p></dd>
</dl>
<p>Each opaque gelcap with a blue cap and white body is spin printed in blue and white ink with â€œPhosLoÂ®â€? printed on the cap and â€œ667 mgâ€? printed on the body.Â  Each gelcap contains 667 mg calcium acetate, USP (anhydrous; Ca(CH<span class="Sub">3</span>COO)<span class="Sub">2</span>; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and 10 mg of the inert binder, polyethylene glycol 8000 NF.Â  The gelatin cap and body have the following inactive ingredients: FD&amp;C blue #1, D&amp;C red #28, titanium dioxide, USP and gelatin, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12Â  CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Patients with ESRD retain phosphorus and can develop <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>.Â  High serum phosphorus can precipitate serum calcium resulting in ectopic calcification.Â  <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">Hyperphosphatemia</span> also plays a role in the development of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in patients with ESRD.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold Italics">12.1Â  MECHANISM OF ACTION
</span></h2>
<p class="First">Calcium acetate, (PhosLoÂ®) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2><span class="Bold Italics">12.2Â  PHARMACODYNAMICS
</span></h2>
<p class="First">Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions.Â  This range represents data from both healthy subjects and renal dialysis patients under various conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13Â  NONCLINICAL TOXICOLOGY
</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold Italics">13.1Â  CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY
</span></h2>
<p class="First">No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1><span class="Bold">14Â  CLINICAL STUDIES
</span></h1>
<p class="First">Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid dosage form.</p>
<p>Ninety-one patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus &gt;5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.</p>
<p>The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks.Â  The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels.Â  The average final dose after 12 weeks of treatment was 3.4 tablets per meal.Â  Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.</p>
<p>The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> in end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients.Â  The effects on serum calcium levels are also presented.</p>
<table frame="void" width="564">
<caption><span> Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time points</span></caption>
<thead><tr class="First Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold">Parameter</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle"><span class="Bold">Pre-Study</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle">
<span class="Bold">Week 4</span><span class="Bold"><span class="Sup">b</span></span>
</td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle"><span class="Bold">Week 8</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle"><span class="Bold">Week 12</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle">
<span class="Bold">p-value</span><span class="Bold"><span class="Sup">c</span></span>
</td>
</tr></thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="6" valign="top">
<span class="Sup">a</span> Values expressed as mean Â± SE. </td></tr>
<tr><td align="left" colspan="6" valign="top">
<span class="Sup">b</span> Ninety-one patients completed at least 6 weeks of the study. </td></tr>
<tr class="Last"><td align="left" colspan="6" valign="top">
<span class="Sup">c</span> ANOVA of difference in values at pre-study and study completion. </td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="middle">Phosphorus (mg/dL)<span class="Sup">a</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">7.4 Â± 0.17</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">5.9 Â± 0.16</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">5.6 Â± 0.17</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">5.2 Â± 0.17</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">â‰¤0.01</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="middle">Calcium (mg/dL)<span class="Sup">a</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">8.9 Â± 0.09</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">9.5 Â± 0.10</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">9.7 Â± 0.10</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">9.7 Â± 0.10</td>
<td class="BotruleLruleRruleToprule" align="center" valign="middle">â‰¤0.01</td>
</tr>
</tbody>
</table>
<p>There was a 30% decrease in serum phosphorus levels during the 12 week study period (p&lt;0.01).Â  Two-thirds of the decline occurred in the first month of the study.Â  Serum calcium increased 9% during the study mostly in the first month of the study.</p>
<p>Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study.Â  Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study.Â  Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.</p>
<p>The phosphate binding effect of calcium acetate is shown in the Table 3.</p>
<table frame="void" width="590">
<caption><span> Table 3: Serum Phosphorus and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm</span></caption>
<thead>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Parameter</span></td>
<td class="BotruleLruleRruleToprule" align="center" rowspan="2" valign="bottom"><span class="Bold"> Pre-Study</span></td>
<td class="BotruleLruleRruleToprule" align="center" colspan="2" valign="top"><span class="Bold">Post-Treatment</span></td>
<td class="BotruleLruleRruleToprule" align="center" rowspan="2" valign="bottom">
<span class="Bold"> p-value</span><span class="Bold"><span class="Sup">b</span></span>
</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="center" valign="bottom"><span class="Italics">Calcium Acetate</span></td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom"><span class="Italics">Placebo</span></td>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" valign="top">
<span class="Sup">a</span> Values expressed as mean Â± SE. </td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top">
<span class="Sup">b</span> ANOVA of calcium acetate vs. placebo after 2 weeks of treatment.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="middle">Phosphorus (mg/dL)<span class="Sup">a</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">7.3 Â± 0.18</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">5.9 Â± 0.24</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">7.8 Â± 0.22</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">&lt;0.01</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="middle">Calcium (mg/dL)<span class="Sup">a</span>
</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">8.9 Â± 0.11</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">9.5 Â± 0.13</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">8.8 Â± 0.12</td>
<td class="BotruleLruleRruleToprule" align="center" valign="bottom">&lt;0.01</td>
</tr>
</tbody>
</table>
<p>Overall, 2 weeks of treatment with calcium acetate statistically significantally (p&lt;0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p&lt;0.01) but clinically unimportant mean of 7%.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING
</span></h1>
<p class="First"><span class="Bold">Gelcap</span> A white and blue gelcap for oral administration containing 667 mg calcium acetate (anhydrous Ca(CH<span class="Sub">3</span>COO)<span class="Sub">2</span>; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium.</p>
<p>Gelcap NDC 49230-640-21 Bottles of 200</p>
<p><span class="Bold">STORAGE</span>:Â  Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [See USP â€œControlled Room Temperatureâ€?].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17Â  PATIENT COUNSELING INFORMATION
</span></h1>
<p class="First">Inform patients to take PhosLoÂ® with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids.Â  Inform the patients about the symptoms of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> <span class="Italics"><a href="#becd383a-2004-4d55-a001-e0353789c6d3">[see Warnings and Precautions (5.1)</a></span><span class="Italics"> and </span><span class="Italics"><a href="#b7f1b1ed-bb8e-4b72-af5f-8f3c5555ac23">Adverse Reactions (6.1)]</a></span><span class="Italics">.</span></p>
<p>Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety and efficacy to take the drug one hour before or three hours after PhosLoÂ®.</p>
<p>Manufactured for</p>
<p>Fresenius Medical Care North America</p>
<p>Waltham, MAÂ  02451</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</span></p>
<div class="Figure"><img alt="99a9c435-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=34a29fae-b549-41ed-bd7d-e98fe2110bef&amp;name=99a9c435-figure-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHOSLOÂ 		
					</strong><br><span class="contentTableReg">calcium acetate capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49230-640</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCIUM ACETATE</strong> (CALCIUM CATION) </td>
<td class="formItem">CALCIUM ACETATE</td>
<td class="formItem">667Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PhosLo;667mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49230-640-21</td>
<td class="formItem">200  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021160</td>
<td class="formItem">04/02/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Fresenius Medical Care North America
							(075684324)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8c973fd0-17a6-11e4-8c21-0800200c9a66</div>
<div>Set id: 34a29fae-b549-41ed-bd7d-e98fe2110bef</div>
<div>Version: 4</div>
<div>Effective Time: 20140804</div>
</div>
</div>Â <div class="DistributorName">Fresenius Medical Care North America</div></p>
</body></html>
